Soligenix announces formation of european medical advisory board for cutaneous t-cell lymphoma

Phase 3 clinical study of hybryte ™ in ctcl initiating in 2024 princeton, n.j. , nov. 19, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a european medical advisory board (mab) to provide additional medical/clinical strategic guidance to the company as it advances its confirmatory phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of hybryte™ (synthetic hypericin) in the treatment of cutaneous t-cell lymphoma (ctcl) patients with early-stage disease.
SNGX Ratings Summary
SNGX Quant Ranking